Madrigal Pharmaceuticals’ Strong Market Position and Promising Outlook Drive Buy Rating
Jefferies analyst Akash Tewari has maintained their bullish stance on MDGL stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal ...
Business Insider15d
Madrigal Pharmaceuticals’ Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $427.00. Discover outperforming stocks and invest ...
JMP Securities Reiterates Market Outperform Rating for Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by equities ...
Stockhouse12d
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...